YNYi Yè Aburi André Nagalo

Yi Yè Aburi André Nagalo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi Yè Aburi André Nagalo has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Heterogeneity of tuberculosis infection across eight selected high-risk populations in Burkina Faso: a cross-sectional study with 18-month follow-up

    by Yi Yè Aburi André Nagalo, Jonathan Hoffmann, Aminata Ouattara, Adama Sourabié, Abdoulaye Sawadogo, Jessica Kambou, Youssouf Baro, Piman Alain-Raphaël Bayili, Odilon Dieudonné Kaboré, Bintou Sanogo, et al.

  • Open Access

    Antimicrobial use and stewardship opportunities in Burkina Faso: findings from the first Global Point Prevalence Survey in eight hospitals

    by André Yi Yè Aburi Nagalo, Ann Versporten, Odilon D. Kaboré, Orokia S. Momo, Noutin F. Michodigni, Bintou Sanogo, Jacques Zoungrana, Ines Pauwels, Ibrahim Traoré, Armel Poda, et al.

    Objective: To describe the prevalence, patterns, and quality indicators of antimicrobial use (AMU) in Burkinabe hospitals and identify priorities for stewardship. Design: Multicentre, cross-sectional point prevalence survey (PPS) following the Global Point Prevalence Survey protocol. Setting: Eight public hospitals across six cities in Burkina Faso (3 primary, 3 secondary, and 2 tertiary), February–June 2019. Participants: All inpatients present on the survey day at 8:00. Medical records were reviewed for those receiving systemic antimicrobial agents. Methods: Standardized ward- and patient-level data were collected on indications, agents, routes, and WHO AWaRe categories, alongside quality indicators (documented indication, stop/review date, guideline compliance, and targeted vs empirical therapy). Descriptive analyses compared hospital tiers. Results: Of 994 inpatients, 729 (73.3%) received ≥1 antimicrobial (range by tier: tertiary 69.7%, secondary 79.2%, primary 79.2%). Community-acquired infections accounted for 96.0% of therapeutic indications. Leading reasons were skin/soft tissue infections (12.2%), gastrointestinal infections (10.7%), and pneumonia (10.4%). Parenteral administration predominated. The most used agents were ceftriaxone (27.8%), metronidazole (15.7%), and gentamicin (9.4%). By AWaRe, Access agents comprised ∼ 50%, Watch agents ∼ 50% overall, with higher Watch use in tertiary hospitals; no Reserve antibiotics were recorded. Quality indicators were suboptimal: the indication was documented in 15.6%, the stop/review date was absent in 93.0%, and 41.1% of prescriptions were guideline-compliant. Therapy was largely empirical (98.5%). Prolonged surgical prophylaxis (>1 day) represented 86.8% of prophylaxis courses. Conclusions: Antimicrobial use (AMU) prevalence in Burkinabe hospitals is high, dominated by empirical therapy and Watch-class ceftriaxone. Deficits in prescribing quality and limited diagnostic use highlight urgent needs for context-adapted antimicrobial stewardship: enforce guideline-concordant care, curb prolonged prophylaxis and unnecessary Watch-class use, and expand affordable microbiology capacity to enable targeted therapy.


  • Open Access

    Dynamiques des méningites à Streptococcus pneumoniae dans un contexte de pression vaccinale au Burkina Faso

    by Hervé Kafando, Samira Guiro, Yi Yè Aburi André Nagalo, D. Odilon Kabore, Kalifa Ouattara, Ismaël Diallo, Issa Tonde, Absetou Ki/Ba, Abdoul-Salam Ouedraogo

    Introduction : Streptococcus pneumoniae demeure l’un des agents majeurs responsables des méningites bactériennes aiguës (MBA) au Burkina Faso. Cette étude vise à décrire la dynamique des sérotypes pneumococciques circulants dans un contexte de pression vaccinale. Méthodologie : Il s’agit d’une étude rétrospective transversale menée sur huit années (2014-2021), correspondant à la période post-vaccinale. Les échantillons de liquide céphalo-rachidien (LCR) issus de la surveillance cas par cas des méningites ont été analysés au CHU Yalgado Ouédraogo pour l’examen cytobactériologique (à partir des milieux trans-isolate) et le diagnostic moléculaire (à partir des cryotubes). Résultats : Sur 5506 échantillons de LCR analysés, 28,8 % étaient positifs à la PCR. La positivité augmentait avec la leucorachie, de 8,1 % pour <10 cellules/mm³ à 70,5 % pour ≥200 cellules/mm³. S. pneumoniae était responsable de 62,3 % des MBA, suivi de Neisseria meningitidis (28 %) et Haemophilus influenzae (9,7 %). La fréquence moyenne des méningites à pneumocoque était de 17,9 %, en baisse de 19,1 % (2014) à 14,5 % (2021). Les sérotypes inclus dans le vaccin PCV13 représentaient 70,8 %, dominés par le sérotype 1 (75,4 %). Les sérotypes non PCV13 constituaient 16,1 %, principalement le 12F/12A/12B/44/46 (65,5 %). Conclusion : La méningite à pneumocoque reste un important problème de santé publique au Burkina Faso. La dynamique évolutive des sérotypes circulants souligne la nécessité d’une surveillance continue pour adapter les stratégies vaccinales.

  • Open Access

    In vitro antibacterial activity of tigecycline against multidrug-resistant bacteria isolated at the Sourô Sanou University teaching hospital in Bobo-Dioulasso, Burkina Faso

    by Odilon D. Kaboré, Mélissa J Gonfouli, Merci Muhigwa, Abdourahmane Sow, Fernand Michodigni, André Nagalo, Jacques Zoungrana, Arsène Hema, Augustin Konkobo, Hervé Kafando, et al.

    Background: Tigecycline, an antibiotic effective against multidrug-resistant bacteria (MDRB), remains inaccessible in Burkina Faso’s hospitals for urgent care. Given the resulting therapeutic challenges and mortality in emergency services, evidence-based study of tigecycline’s efficacy on local bacterial clinical isolates is necessary before recommending its use. Objective: This study aimed to evaluate the activity of tigecycline on MDRB isolates at the Sourô Sanou University Teaching Hospital laboratory, Burkina Faso. Methods: This was a cross-sectional study with prospective and consecutive sampling of MDRBs. The latter included extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant strains (CRS), and methicillin-resistant Staphylococcus aureus (MRSA), which were isolated from urine, blood, pus and puncture fluids between 01 June 2022 and 31 August 2022. Antimicrobial susceptibility testing was conducted using the modified Kirby-Bauer method, and the results were interpreted according to the standard set by the European Committee on Antimicrobial Susceptibility Testing in 2021. Results: A total of 117 MDRBs, including 93 Enterobacterales, 15 carbapenem-resistant Acinetobacter baumannii (CRAB), and 9 MRSAs were collected. The proportion of ESBL-E was 58% (68/117), followed by CRS (34%, 40/117) and MRSA (8%, 9/117). The activity of tigecycline was 95.5% (43/45) on ESBL-E, 72.5% (29/40) on CRS (including 10/15 CRAB), and 89% (8/9) on MRSA. Conclusion: The activity of tigecycline was highly effective on ESBL-E, carbapenem resistant Enterobacterales and MRSA, and moderate on CRAB. What this study adds: This was the first report on the evaluation of tigecycline activity on MDRBs in Burkina Faso. This non-marketed antibiotic in Burkina Faso could represent an alternative to spare carbapenems in the treatment of ESBL-E infections, and a last resort antibiotic against susceptible CRS infections in Burkina Faso’s hospitals.

  • Open Access

    Molecular epidemiology of tuberculosis in Western Burkina Faso: insights from a MIRU-VNTR study

    by Yi Yè Aburi André Nagalo, Odilon D. Kaboré, Anselme Millogo, Adama Sourabié, Emmanuel Zongo, Cheick Ahmed Ouattara, Yacouba Sawadogo, Jacques Kaboré, Emile Birba, Armel Poda, et al.

    Tuberculosis (TB) remains a significant public health challenge in Burkina Faso, with limited molecular epidemiology data available to track strain diversity and transmission patterns. This study aims to characterize the genetic diversity of Mycobacterium tuberculosis complex (MTBC) isolates circulating in Burkina Faso via Mycobacterial Interspersed Repetitive-Unit Variable-Number Tandem-Repeat (MIRU-VNTR) typing. Genotyping via the MIRU-VNTR technique, which is based on 24 loci, was performed via PCR amplification of DNA extracts from 80 MTBC isolates, followed by agarose gel electrophoresis. The genotypes obtained were identified via comparison with reference strains in the database via the MIRU VNTRplus web application. This study assessed strain diversity, clustering rates, and potential transmission patterns in the study area. Among the 80 isolates, 94.5% were identified as M. tuberculosis sensu stricto, while 2.7% were M. africanum and 2.7% were M. bovis. The predominant lineages were Cameroon (26.3%), Ghana (26.3%), and Haarlem (20%), with the Beijing lineage being rare (1.25%). A low clustering rate of 2.5% was observed. The average discriminating power (allelic diversity index) was 0.444. Eight loci were highly discriminative (h ≥ 0. 6) versus 3 loci that were weakly discriminating (h < 0.3). This study provides new insights into the genetic diversity and transmission dynamics of MTBC strains in Burkina Faso. While the observed low clustering suggests limited recent TB transmission, the findings require further validation through larger-scale studies incorporating whole-genome sequencing (WGS). Understanding TB strain diversity is crucial for optimizing diagnostic strategies and TB control policies in West Africa.


  • Comparing antibiotic susceptibility profiles of urinary tract infection isolates in a University Hospital in Burkina Faso: Community vs. hospital profiles

    by Nagalo Andre, Kabore DieudonnÉ Odilon, Kissou Senkaye-Lagom AimÉE, Mahamoud Issaka Ali, Kabre Boukary, Semde Aoua, Ouattara Cheick Ahmed, Sawadogo Yacouba, Zoungrana Jacques, Poda Armel, et al.

    Background: The emergence of antimicrobial resistance (AMR) within bacterial pathogens necessitates a local comprehension of the epidemiological context. This information is indispensable for clinical therapeutic determinations and the reevaluation of prevailing care protocols. This study aimed to highlight the antibiotic susceptibility profile of uropathogenic bacteria isolated within a University Hospital in Burkina Faso, focusing on enhancing probabilistic antibiotic therapy for community and hospital-based urinary tract infections (UTIs). Methodology: Data from cytological urine analysis and antimicrobial susceptibility testing spanning 29 months (January 2017 to May 2019) was retrospectively collected and systematically analysed. Results: In both hospital and community based UTIs, Enterobacterales dominated, constituting 79.86% (81.27% vs. 79.11%) of isolates. This is followed by Non-fermentative Gram-Negative Bacteria at 6.60% (6.35% vs. 6.88%) and Gram-Positive Cocci at 6.41% (7.98% vs. 5.57%). Escherichia coli (61.37%), Klebsiella pneumoniae (10.66%), and Enterobacter spp. emerged as the predominant pathogens in the same rank regardless of the origin of the ITUs. Imipenem (97.19%), amikacin (69.26%), ceftriaxone (58.44%), and ciprofloxacin (47.60%) displayed superior susceptibility against all uropathogens. Subtle but significant variations emerged between hospital and community strains' susceptibility to various antibiotics, including amoxicillin + clavulanic acid (26.05% vs. 32.26%), Imipenem (96.43% vs. 98.59%), and ciprofloxacin (45.51% vs. 51.41%). Conclusion: Penicillins showcased diminished efficacy against uropathogens, while resistance to fluoroquinolones escalated. The combined use of aminoglycosides and third-generation cephalosporins holds promise as an optimal probabilistic therapy for UTIs. The profiles of hospital and community UTIs showed substantial similarities in terms of implicated uropathogens, yet hospital strains demonstrated higher resistance levels.

  • Open Access

    Automated blood culture systems for isolation of bacterial pathogens of bloodstream infection: The experience of Bobo-Dioulasso Teaching Hospital, Burkina Faso

    by A. Nagalo, O.D. Kabore, M. Koulbou, B. Sanogo, C.L. Yehouenou, I. Traore, J. Zoungrana, A. Poda, A-S. Ouedraogo

    Background: Identification of the causative agent is an essential requirement for better treatment of bloodstream infection. The BacT/Alert 3D (BioMérieux, Marcy l’Étoile, France), is a blood culture system equipped with CO2 sensors to monitor the growth of microorganisms in blood culture bottles designed to optimize bacterial growth. The aim of this study was to determine the performance of this equipment in detecting bacterial pathogens from patients with bloodstream infection in the context of low-and-middle-income countries (LMICs), with Bobo-Dioulasso Teaching Hospital as a case study. Methodology: A cross-sectional study was conducted over a period of 5 months at the Sourô Sanou University Hospital, Bobo-Dioulasso, Burkina Faso, a low-income country. Blood samples from a total of 231 patients with clinical suspicion of bloodstream infections were collected and processed according to the manufacturer's instructions. Results: Sixty-nine of the 231 blood culture samples of patients were positive, giving a bacteriological yield of 29.9%. Escherichia coli, Salmonella spp, and Staphylococcus aureus were the top three bacterial species isolated. Conclusion: The implementation of the BacT/Alert 3D system has significantly enhanced the diagnosis of bacteraemia in the Bobo-Dioulasso Teaching Hospital. This enhancement is marked by time savings in patient care, reduced staff workload, and an increased bacteriological yield over time.